Targeting L-type amino acid transporter 1 in urological malignancy: Current status and future perspective

被引:5
作者
Pae, Sangjon [1 ,2 ]
Sakamoto, Shinichi [1 ,4 ]
Zhao, Xue [1 ]
Saito, Shinpei [1 ,2 ]
Tamura, Takaaki [1 ]
Imamura, Yusuke [1 ]
Sazuka, Tomokazu [1 ]
Reien, Yoshie [2 ]
Hirayama, Yuri [2 ]
Hashimoto, Hirofumi [2 ]
Kanai, Yoshikatsu [3 ]
Ichikawa, Tomohiko [1 ]
Anzai, Naohiko [2 ]
机构
[1] Chiba Univ, Grad Sch Med, Dept Urol, Chiba, Japan
[2] Chiba Univ, Grad Sch Med, Dept Pharmacol, Chiba, Japan
[3] Osaka Univ, Grad Sch Med, Biosyst Pharmacol, Osaka, Japan
[4] Chiba Univ, Grad Sch Med, 1-8-1 Inohana,Chuo Ku, Chiba, Chiba 2608670, Japan
关键词
LAT1; Prostate cancer; Renal cancer; Bladder cancer; HEAVY-CHAIN; FUNCTIONAL-CHARACTERIZATION; MEMBRANE-PROTEIN; CD98; EXPRESSION; CANCER; LAT1; IDENTIFICATION; CLONING; MTORC1; THERAPY;
D O I
10.1016/j.jphs.2022.10.002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Amino acid transporters are responsible for the uptake of amino acids, critical for cell proliferation. L -type amino acid transporters play a major role in the uptake of essential amino acids. L-type amino acid transporter 1 (LAT1) exerts its functional properties by forming a dimer with 4F2hc. Utilizing this cancer -specificity, research on diagnostic imaging and therapeutic agents for malignant tumors targeting LAT1 progresses in various fields. In hormone-sensitive prostate cancer, the up-regulation of L-type amino acid transporter 3 (LAT3) through the androgen receptor (AR) has been identified. On the other hand, in castration-resistant prostate cancer, the negative regulation of LAT1 through AR has been determined. Furthermore, 4F2hc: a binding partner of LAT1, was identified as the specific downstream target of Androgen Receptor Splice Variant 7: AR-V7. LAT1 has been suggested to contribute to acquiring castration resistance in prostate cancer, making LAT1 a completely different therapeutic target from anti-androgens and taxanes. Increased expression of LAT1 has also been found in renal and bladder cancers, suggesting a contribution to acquiring malignancy and progression. In Japan, clinical trials of LAT1 inhibitors for solid tumors are in progress, and clinical applications are now underway. This article will summarize the relationship between LAT1 and urological malignancies.(c) 2022 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/lice nses/by-nc-nd/4.0/).
引用
收藏
页码:251 / 258
页数:8
相关论文
共 68 条
[1]   AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer [J].
Antonarakis, Emmanuel S. ;
Lu, Changxue ;
Wang, Hao ;
Luber, Brandon ;
Nakazawa, Mary ;
Roeser, Jeffrey C. ;
Chen, Yan ;
Mohammad, Tabrez A. ;
Chen, Yidong ;
Fedor, Helen L. ;
Lotan, Tamara L. ;
Zheng, Qizhi ;
De Marzo, Angelo M. ;
Isaacs, John T. ;
Isaacs, William B. ;
Nadal, Rosa ;
Paller, Channing J. ;
Denmeade, Samuel R. ;
Carducci, Michael A. ;
Eisenberger, Mario A. ;
Luo, Jun .
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (11) :1028-1038
[2]   Identification of a novel system L amino acid transporter structurally distinct from heterodimeric amino acid transporters [J].
Babu, E ;
Kanai, Y ;
Chairoungdua, A ;
Kim, DK ;
Iribe, Y ;
Tangtrongsup, S ;
Jutabha, P ;
Li, YW ;
Ahmed, N ;
Sakamoto, S ;
Anzai, N ;
Nagamori, S ;
Endou, H .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (44) :43838-43845
[3]   Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma [J].
Bellmunt, J. ;
de Wit, R. ;
Vaughn, D. J. ;
Fradet, Y. ;
Lee, J. -L. ;
Fong, L. ;
Vogelzang, N. J. ;
Climent, M. A. ;
Petrylak, D. P. ;
Choueiri, T. K. ;
Necchi, A. ;
Gerritsen, W. ;
Gurney, H. ;
Quinn, D. I. ;
Culine, S. ;
Sternberg, C. N. ;
Mai, Y. ;
Poehlein, C. H. ;
Perini, R. F. ;
Bajorin, D. F. .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (11) :1015-1026
[4]   Increased expression of system large amino acid transporter (LAT)-1 mRNA is associated with invasive potential and unfavorable prognosis of human clear cell renal cell carcinoma [J].
Betsunoh, Hironori ;
Fukuda, Takehiko ;
Anzai, Naohiko ;
Nishihara, Daisaku ;
Mizuno, Tomoya ;
Yuki, Hideo ;
Masuda, Akinori ;
Yamaguchi, Yoshiyuki ;
Abe, Hideyuki ;
Yashi, Masahiro ;
Fukabori, Yoshitatsu ;
Yoshida, Ken-Ichiro ;
Kamai, Takao .
BMC CANCER, 2013, 13
[5]   Identification of LAT4, a novel amino acid transporter with system L activity [J].
Bodoy, S ;
Martín, L ;
Zorzano, A ;
Palacín, M ;
Estévez, R .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (12) :12002-12011
[6]   The role of amino acid transporters in inherited and acquired diseases [J].
Broeer, Stefan ;
Palacin, Manuel .
BIOCHEMICAL JOURNAL, 2011, 436 :193-211
[7]   Expression of the surface antigen 4F2hc affects system-L-like neutral-amino-acid-transport activity in mammalian cells [J].
Broer, S ;
Broer, A ;
Hamprecht, B .
BIOCHEMICAL JOURNAL, 1997, 324 :535-541
[8]   Dual role of ER stress in response to metabolic co-targeting and radiosensitivity in head and neck cancer cells [J].
Chen, Oleg ;
Manig, Friederike ;
Lehmann, Loreen ;
Sorour, Nagwa ;
Lock, Steffen ;
Yu, Zhanru ;
Dubrovska, Anna ;
Baumann, Michael ;
Kessler, Benedikt M. ;
Stasyk, Oleh ;
Kunz-Schughart, Leoni A. .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2021, 78 (06) :3021-3044
[9]   LAT1 (SLC7A5) and CD98hc (SLC3A2) complex dynamics revealed by single-particle cryo-EM [J].
Chiduza, George N. ;
Johnson, Rachel M. ;
Wright, Gareth S. A. ;
Antonyuk, Svetlana, V ;
Muench, Stephen P. ;
Hasnain, S. Samar .
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY, 2019, 75 :660-669
[10]   Genetic Disruption of the Multifunctional CD98/LAT1 Complex Demonstrates the Key Role of Essential Amino Acid Transport in the Control of mTORC1 and Tumor Growth [J].
Cormerais, Yann ;
Giuliano, Sandy ;
LeFloch, Renaud ;
Front, Benoit ;
Durivault, Jerome ;
Tambutte, Eric ;
Massard, Pierre-Andre ;
Rodriguez de la Ballina, Laura ;
Endou, Hitoshi ;
Wempe, Michael F. ;
Palacin, Manuel ;
Parks, Scott K. ;
Pouyssegur, Jacques .
CANCER RESEARCH, 2016, 76 (15) :4481-4492